Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk
Bitget2026/09/27 22:05- Abbott flagged new real-world data linking continuous glucose monitoring use to fewer deaths in Type 2 diabetes patients on basal insulin.
- Results will be presented at EASD starting Sept. 28, 2026, supporting broader adoption of Libre in a large insulin-treated population.
- A separate observational analysis tied Libre use to fewer hospitalizations for acute diabetes events in Type 2 diabetes patients.
- Abbott also plans to present additional FreeDM2 trial analyses showing faster, sustained improvements in glucose control following Libre 3 initiation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
To prevent liquidity support from being seen as QE, Federal Reserve's Logan proposes separate accounting for market functioning bond purchases and accelerated sales.
Dallas Federal Reserve President Lorie Logan stated that the Federal Reserve should completely separate market-functionality bond purchases from monetary policy operations, record them independently, and commit to selling them as soon as possible in order to dispel market concerns over the Fed potentially suppressing long-term yields. She emphasized that a full understanding of the Fed’s decision-making logic by the market itself has a stabilizing effect.
Organigram Receives Nasdaq Notice for Minimum Bid Price Noncompliance
Custom Health publishes update to financial calendar
Crypto prices
More
